Evolent Health Inc. (NYSE:EVH) COO Thomas Peterson III sold 72,827 shares of the stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total value of $1,568,693.58. Following the completion of the sale, the chief operating officer now directly owns 377,623 shares of the company’s stock, valued at $8,133,999.42. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Evolent Health Inc. (NYSE:EVH) opened at 22.71 on Tuesday. The firm has a 50-day moving average price of $24.35 and a 200-day moving average price of $17.14. The company’s market cap is $1.37 billion. Evolent Health Inc. has a 52 week low of $8.14 and a 52 week high of $26.84.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.04. The firm had revenue of $56.50 million for the quarter, compared to analyst estimates of $51.96 million. Evolent Health had a negative return on equity of 5.04% and a negative net margin of 76.55%. The business’s quarterly revenue was up 443.3% compared to the same quarter last year. During the same period last year, the company earned ($0.95) EPS. Equities research analysts anticipate that Evolent Health Inc. will post ($0.54) EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Barclays PLC purchased a new stake in Evolent Health during the second quarter valued at $144,000. American International Group Inc. raised its stake in Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares in the last quarter. Nationwide Fund Advisors raised its stake in Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Evolent Health during the second quarter valued at $199,000. Finally, Alliancebernstein L.P. purchased a new stake in Evolent Health during the second quarter valued at $278,000. Hedge funds and other institutional investors own 42.07% of the company’s stock.

A number of research firms recently commented on EVH. Canaccord Genuity began coverage on Evolent Health in a research report on Wednesday, June 1st. They issued a “buy” rating for the company. FBR & Co increased their price target on Evolent Health from $16.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, July 13th. Leerink Swann reissued an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a research report on Sunday, July 17th. Finally, Jefferies Group began coverage on Evolent Health in a research report on Tuesday, July 26th. They issued a “buy” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $22.50.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.